GO
Loading...

Merck & Co Inc

More

  • Dec 23- The U.S. Department of Health and Human Services awarded contracts worth a total of about $43 million to NewLink Genetics Corp and GlaxoSmithKline Plc for faster development of two Ebola vaccines. Under a $30 million contract, NewLink's unit BioProtection Systems Corp will conduct clinical trials to determine the lowest dose at which its vaccine...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • LOS ANGELES, Dec 23- Express Scripts, the largest manager of prescription drug plans for U.S. employers, is taking an increasingly aggressive stance in price negotiations with pharmaceutical companies after winning discounts on medications with a strategy introduced last year. On Monday, Express Scripts said it lined up a cheaper price for AbbVie Inc's newly...

  • Dec 22- The U.S. Food and Drug Administration approved Bristol-Myers Squibb Co's skin cancer drug, more than three months before the scheduled review date. The drug is the second PD-1 inhibitor to be approved by the FDA, the first being Merck& Co Inc's Keytruda in September. The FDA was scheduled to review the drug on March 30.

  • FDA OKs Cubist antibiotic for serious infections Friday, 19 Dec 2014 | 6:34 PM ET

    TRENTON, N.J.— The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May. The approval of Zerbaxa on Friday is the second antibiotic approval this year for Cubist Pharmaceuticals, a drugmaker focused on antibiotics. It is being acquired for...

  • Dec 19- Cubist Pharmaceutical Inc's drug to treat complicated urinary tract and intra-abdominal infections won U.S. approval on Friday, highlighting the regulator's interest in tackling the growing threat of the so-called superbugs. Zerbaxa is the fourth new antibacterial drug approved by the FDA this year. The agency approved Actavis Plc's Dalvance in...

  • Merck buys Swiss biotech with promising cancer drug Thursday, 18 Dec 2014 | 12:16 PM ET

    KENILWORTH, N.J.— Drugmaker Merck says it's bought a Swiss biotech company developing cancer drugs as part of its strategy to be a top player in cancer, one of the hottest pharmaceutical research areas. Merck& Co., based in Kenilworth, New Jersey, will pay up to $110 million upfront to OncoEthix. The privately held company could receive further payments of up to $265...

  • *Shares in GSK partner Agenus jump 10 percent. LONDON, Dec 18- An experimental shingles vaccine from GlaxoSmithKline has produced impressive results in a late-stage study, giving the group's expanding vaccine unit a potential $1 billion boost. The data suggests the British company's new shot could be a strong competitor for Merck& Co's established vaccine...

  • LONDON, Dec 18- An experimental vaccine against shingles from GlaxoSmithKline met its goal in a late-stage study, in a boost for the company's vaccine unit, which is expanding part of its overall healthcare business. The adjuvant includes a component from U.S. biotech firm Agenus, which is entitled to royalties on any future sales. Merck& Co already sells another...

  • Dec 17- Amgen Inc on Wednesday said its new type of treatment for a deadly form of leukemia would cost about $178,000 when it becomes available on Thursday, which would make it one of the world's most expensive cancer drugs. "We believe the price reflects the significant clinical, economic and humanistic value of the product to patients and the healthcare system,...

  • Dec 12- Cempra Inc has no plans for now to sell itself, its CEO said, brushing off talk that the company is a potential target as big drugmakers set their sights on antibiotic developers. The deal stirred speculation that developers such as Cempra could also be takeover targets. I know a lot of other biotechs are, " Cempra Chief Executive Prabha Fernandes said in an...

  • NEW YORK/ WASHINGTON, Dec 11- U.S. prosecutors, already smarting from a appeals court ruling that weakens their ability to crack down on future insider trading, on Thursday faced widening fallout from the decision as some existing cases threatened to unravel. Lawyers for some defendants hinted they might seek to withdraw guilty pleas, and a Manhattan federal...

  • LONDON, Dec 10- Drugmakers are finally getting more bang for their scientific buck, with the rate of return on pharmaceutical research and development increasing for the first time since 2010.. So far this year the U.S. Food and Drug Administration, which acts as gatekeeper to the world's biggest market, has approved 35 new products, up from 27 in the whole of 2013...

  • Cramer's personal connection to Merck acquisition Monday, 8 Dec 2014 | 6:48 PM ET
    A researcher works in a microbiology laboratory at the Cubist Pharmaceuticals research facility in Lexington, Massachusetts.

    Jim Cramer has a personal connection to why he approves of Merck's acquisition of Cubist. Find out why.

  • Trader on the floor of the New York Stock Exchange.

    Stocks declined Monday as trade numbers from China came in below expectations and oil companies were knocked by the falling price of crude.

  • $9.5 billion blockbuster drug deal  Monday, 8 Dec 2014 | 1:01 PM ET

    Following Merck's acquisition of Cubist, chairman and CEO Kenneth Frazier discusses innovation possibilities the deal presents for public health, with CNBC's Meg Tirrell.

  • Cubist options unusually active before Merck deal Monday, 8 Dec 2014 | 12:50 PM ET

    NEW YORK, Dec 8- Cubist Pharmaceuticals Inc options had one of their most active weeks this year last week ahead of Monday's announcement that Merck& Co will buy Cubist for a hefty premium. Merck said it will pay $102 a share for Cubist, 37 percent above the Lexington, Massachussetts, company's closing share price of $74.36 on Friday. Implied volatility jumped to...

  • NEW YORK, Dec 8- U.S. stocks were little changed on Monday, as investors weighed the strength of the U.S. economy against global growth concerns following soft data out of China and Japan, while biotechs rose on merger activity. Major indexes opened slightly lower after data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7...

  • Merck CEO: Biotech valuations reflect optimism  Monday, 8 Dec 2014 | 10:17 AM ET

    Merck agreed to acquire Cubist Pharmaceuticals in a $9.5 billion deal. CNBC's Meg Tirrell discusses the price of the deal and patent challenges Merck may face.

  • NEW YORK, Dec 8- U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. Data showed China's exports grew at a slower-than-expected pace and imports dropped 6.7 percent in November, while Japan's economy shrank more than expected in the third quarter.